Black Diamond Therapeutics, Inc.
corporate_fare Company Profile
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for BDTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for BDTX spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Black Diamond 10-Q: $102M Cash Into H2 2028, Q3 Net Loss $10.0M
- Silevertinib Shows 86% CNS Response Rate in Untreated Brain Metastases
- Black Diamond's Silevertinib Hits 86% CNS-ORR; FDA Backs Path to Registration
- Black Diamond Sets Nov. 10 Webcast on Silevertinib Phase 2 Data and FDA-Backed Phase 3 Path
- Black Diamond Therapeutics Reports Positive Phase 2 Silevertinib Results in NSCLC, Plans FDA Meeting
Financial Snapshot
Short Interest & Short Volume
4.87 days to coverFINRA reported short interest of 5,106,005 shares in BDTX as of the October 30, 2026 settlement, a 2.1% increase from the prior period — about 4.9 days to cover at its recent average daily volume. On November 20, 2026, 49.2% of BDTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.